Jazz Pharmaceuticals (JAZZ) Set to Announce Earnings on Wednesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) will issue its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of $3.55 per share for the quarter. Jazz Pharmaceuticals has set its FY24 guidance at $18.15-$19.35 EPS and its FY 2024 guidance at 18.150-19.350 EPS.Parties interested in participating in the company’s conference call can do so using this link.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1.01 billion. On average, analysts expect Jazz Pharmaceuticals to post $16 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Jazz Pharmaceuticals Stock Up 0.8 %

JAZZ stock opened at $109.67 on Wednesday. Jazz Pharmaceuticals has a 1-year low of $106.61 and a 1-year high of $146.70. The business has a fifty day moving average price of $119.26 and a 200-day moving average price of $122.14. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. The stock has a market capitalization of $6.91 billion, a P/E ratio of 17.92, a P/E/G ratio of 1.52 and a beta of 0.59.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CFO Philip L. Johnson purchased 12,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Philip L. Johnson purchased 12,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on JAZZ. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 30th. Stifel Nicolaus boosted their price target on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Barclays decreased their price target on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, March 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $195.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Finally, UBS Group cut their price objective on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a report on Friday, March 1st. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $195.08.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.